Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum

14 Mar 2025

Abstract excerpt

Changes in β-amyloid (Aβ) and hyperphosphorylated tau (T) in brain and cerebrospinal fluid (CSF) precede Alzheimer's disease (AD) symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable diagnostics and therapies. Using the AT framework and a three-stage study design (discovery, replication, and meta-analysis), we identified 2,173 analytes (2,029 unique...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Bioinformatics and Genomic Networks
Share to Metabolomics and Mass Spectrometry Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40088886
DOI: 10.1016/j.neuron.2025.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumPMID 40088886Read ↗

CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease.Semantic proximity Read ↗

Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersSemantic proximity Read ↗

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's diseaseSemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panelsSemantic proximity Read ↗

Systematic proteomics in Autosomal dominant Alzheimer’s disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathwaysSemantic proximity Read ↗

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity Read ↗

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and agingSemantic proximity Read ↗

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

Multi-tissue proteomic signatures of Alzheimer’s disease: a systematic investigation in brain, CSF, blood and an exploratory study in tearsSemantic proximity Read ↗

Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer’s diseaseSemantic proximity Read ↗

Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.